M
Maria Koltowska-Häggström
Researcher at Uppsala University
Publications - 89
Citations - 3072
Maria Koltowska-Häggström is an academic researcher from Uppsala University. The author has contributed to research in topics: Growth hormone deficiency & Population. The author has an hindex of 31, co-authored 89 publications receiving 2807 citations. Previous affiliations of Maria Koltowska-Häggström include Uppsala University Hospital & Pfizer.
Papers
More filters
Journal ArticleDOI
The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients.
Helena Filipsson,John P Monson,Maria Koltowska-Häggström,Maria Koltowska-Häggström,Anders F Mattsson,Gudmundur Johannsson +5 more
TL;DR: Heq doses of at least 20 mg/d in adults with hypopituitarism are associated with an unfavorable metabolic profile, and CA replacement may have metabolic advantages compared with other GCs.
Journal ArticleDOI
Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY
A. J. van der Lely,Beverly M. K. Biller,Thierry Brue,Michael Buchfelder,Ezio Ghigo,Roy Gomez,Judith Hey-Hadavi,Frida Lundgren,Natasa Rajicic,Christian J. Strasburger,Susan M. Webb,Maria Koltowska-Häggström +11 more
TL;DR: Data entered and evaluated in ACROSTUDY indicate that pegvisomant is an effective and safe medical treatment in patients with acromegaly and the reported low incidence of pituitary tumor size increase, liver enzyme elevations, and lipodystrophy at the injection site are reassuring.
Journal ArticleDOI
Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis.
Roger Abs,Ulla Feldt-Rasmussen,Anders F Mattsson,John P Monson,Bengt-Åke Bengtsson,Miklós Góth,Patrick Wilton,Maria Koltowska-Häggström,Maria Koltowska-Häggström +8 more
TL;DR: The sustained improvement of the adverse lipid profile and body composition suggests that GH replacement therapy may reduce the risk of cardiovascular disease and the premature mortality seen in hypopituitary patients with untreated GHD.
Journal ArticleDOI
Overall and cause-specific mortality in GH-deficient adults on GH replacement.
Rolf-Christian Gaillard,Anders F Mattsson,Ann-Charlotte Åkerblad,Bengt-Åke Bengtsson,Jose Cara,Ulla Feldt-Rasmussen,Maria Koltowska-Häggström,John P. Monson,Bernhard Saller,Patrick Wilton,Roger Abs +10 more
TL;DR: In this article, the authors evaluated mortality and associated factors within a large GH-replaced population of hypopituitary patients, and showed that GH replacement in hypopITuitary adults with GH deficiency may be considered a safe treatment.
Journal ArticleDOI
The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma
Pat Kendall-Taylor,Peter Jonsson,Roger Abs,Eva Marie Erfurth,Maria Koltowska-Häggström,David A. Price,Johan Verhelst +6 more
TL;DR: Quality of life, assessed by Quality of Life-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) and the Nottingham Health Profile, was markedly reduced in all groups with no significant differences between them.